Certified by Founder Lodge
OrbiMed
United States - New York, NY INVESTOR
1 Disclosed Funding Rounds $261,000,000
94 Participating Investments
- Operating Status
Active
- Last Funding Type
Seed
- Company Type
For Profit
- Website
- Contact
- Social Links
OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit f
| Company | Date | Round | Raised |
|---|---|---|---|
 Adela, Inc. | September, 26 ,2023 | Unknown | $48,000,000 |
 CHARM Therapeutics | June, 09 ,2022 | Series A | $50,000,000 |
 Star Therapeutics | September, 05 ,2023 | Series C | $90,000,000 |
 Treeline Biosciences | October, 18 ,2022 | Series A | $261,000,000 |
 Evozyne | September, 28 ,2023 | Series B | $81,000,000 |
 Congruence Therapeutics | March, 07 ,2023 | Series A | $65,000,000 |
 Corteria Pharmaceuticals | September, 07 ,2023 | Series A | $69,471,000 |
 Delfi Diagnostics | July, 18 ,2022 | Series B | $225,000,000 |
 Aer Therapeutics, Inc. | April, 17 ,2023 | Series A | $36,000,000 |
 Iambic Therapeutics | October, 06 ,2023 | Series B | $100,000,000 |
 Pathalys Pharma | February, 07 ,2023 | Unknown | $150,000,000 |
 ReCode Therapeutics | September, 20 ,2023 | Series B | $50,000,000 |
 Convergent Therapeutics, Inc. | May, 04 ,2023 | Series A | $90,000,000 |
 Rampart Bioscience | October, 25 ,2023 | Series A | $85,000,000 |
| CHARM Therapeutics | June, 09 ,2022 | Series A | $50,000,000 |
| Adela, Inc. | September, 26 ,2023 | Unknown | $48,000,000 |
 ADARx Pharmaceuticals Inc. | August, 10 ,2023 | Series C | $200,000,000 |
 Triveni Bio | October, 27 ,2023 | Series A | $92,000,000 |
| Congruence Therapeutics | March, 07 ,2023 | Series A | $65,000,000 |
| Evozyne | September, 28 ,2023 | Series B | $81,000,000 |
 Fore Biotherapeutics | August, 25 ,2023 | Series D | $75,000,000 |
 Forward Therapeutics, Inc. | November, 09 ,2023 | Series A | $50,000,000 |
| Aer Therapeutics, Inc. | April, 17 ,2023 | Series A | $36,000,000 |
| Iambic Therapeutics | October, 06 ,2023 | Series B | $100,000,000 |
 Epigenic Therapeutics | August, 30 ,2023 | Series A | $32,000,000 |
 Koya Medical, Inc. | November, 16 ,2023 | Unknown | $30,000,000 |
| Convergent Therapeutics, Inc. | May, 04 ,2023 | Series A | $90,000,000 |
| Rampart Bioscience | October, 25 ,2023 | Series A | $85,000,000 |
| Star Therapeutics | September, 05 ,2023 | Series C | $90,000,000 |
 Odyssey Therapeutics | December, 06 ,2023 | Series C | $101,000,000 |
| ADARx Pharmaceuticals Inc. | August, 10 ,2023 | Series C | $200,000,000 |
| Triveni Bio | October, 27 ,2023 | Series A | $92,000,000 |
| Corteria Pharmaceuticals | September, 07 ,2023 | Series A | $69,471,000 |
 Noctrix Health, Inc. | January, 17 ,2024 | Series C | $40,000,000 |
| Fore Biotherapeutics | August, 25 ,2023 | Series D | $75,000,000 |
| Forward Therapeutics, Inc. | November, 09 ,2023 | Series A | $50,000,000 |
| ReCode Therapeutics | September, 20 ,2023 | Series B | $50,000,000 |
 Sionna Therapeutics | March, 07 ,2024 | Series C | $182,000,000 |
| Epigenic Therapeutics | August, 30 ,2023 | Series A | $32,000,000 |
| Koya Medical, Inc. | November, 16 ,2023 | Unknown | $30,000,000 |
| Adela, Inc. | September, 26 ,2023 | Unknown | $48,000,000 |
 Capstan Therapeutics | March, 21 ,2024 | Series B | $175,000,000 |
| Star Therapeutics | September, 05 ,2023 | Series C | $90,000,000 |
| Odyssey Therapeutics | December, 06 ,2023 | Series C | $101,000,000 |
| Evozyne | September, 28 ,2023 | Series B | $81,000,000 |
 Mirador Therapeutics | March, 26 ,2024 | Unknown | $400,000,000 |
| Corteria Pharmaceuticals | September, 07 ,2023 | Series A | $69,471,000 |
| Noctrix Health, Inc. | January, 17 ,2024 | Series C | $40,000,000 |
| Iambic Therapeutics | October, 06 ,2023 | Series B | $100,000,000 |
 Alterome Therapeutics, Inc | April, 09 ,2024 | Series B | $132,000,000 |
| ReCode Therapeutics | September, 20 ,2023 | Series B | $50,000,000 |
| Sionna Therapeutics | March, 07 ,2024 | Series C | $182,000,000 |
| Rampart Bioscience | October, 25 ,2023 | Series A | $85,000,000 |
 Scorpion Therapeutics | July, 17 ,2024 | Series C | $150,000,000 |
| Adela, Inc. | September, 26 ,2023 | Unknown | $48,000,000 |
| Triveni Bio | October, 27 ,2023 | Series A | $92,000,000 |
| Capstan Therapeutics | March, 21 ,2024 | Series B | $175,000,000 |
| Evozyne | September, 28 ,2023 | Series B | $81,000,000 |
| Mirador Therapeutics | March, 26 ,2024 | Unknown | $400,000,000 |
| Forward Therapeutics, Inc. | November, 09 ,2023 | Series A | $50,000,000 |
| Alterome Therapeutics, Inc | April, 09 ,2024 | Series B | $132,000,000 |
| Iambic Therapeutics | October, 06 ,2023 | Series B | $100,000,000 |
| Scorpion Therapeutics | July, 17 ,2024 | Series C | $150,000,000 |
 Candid Therapeutics | September, 10 ,2024 | Unknown | $370,000,000 |
| Koya Medical, Inc. | November, 16 ,2023 | Unknown | $30,000,000 |
 Leal Therapeutics | October, 31 ,2024 | Unknown | $45,000,000 |
| Rampart Bioscience | October, 25 ,2023 | Series A | $85,000,000 |
 Adcendo | November, 26 ,2024 | Series B | $135,000,000 |
| Odyssey Therapeutics | December, 06 ,2023 | Series C | $101,000,000 |
 Angitia Biopharmaceuticals | December, 12 ,2024 | Series C | $120,000,000 |
| Triveni Bio | October, 27 ,2023 | Series A | $92,000,000 |
| Noctrix Health, Inc. | January, 17 ,2024 | Series C | $40,000,000 |
 Aerin Medical | January, 14 ,2025 | Unknown | $32,500,000 |
| Forward Therapeutics, Inc. | November, 09 ,2023 | Series A | $50,000,000 |
 Curevo Vaccine | March, 19 ,2025 | Series B | $110,000,000 |
| Sionna Therapeutics | March, 07 ,2024 | Series C | $182,000,000 |
| Koya Medical, Inc. | November, 16 ,2023 | Unknown | $30,000,000 |
| Capstan Therapeutics | March, 21 ,2024 | Series B | $175,000,000 |
| Odyssey Therapeutics | December, 06 ,2023 | Series C | $101,000,000 |
| Mirador Therapeutics | March, 26 ,2024 | Unknown | $400,000,000 |
| Noctrix Health, Inc. | January, 17 ,2024 | Series C | $40,000,000 |
| Alterome Therapeutics, Inc | April, 09 ,2024 | Series B | $132,000,000 |
| Sionna Therapeutics | March, 07 ,2024 | Series C | $182,000,000 |
| Scorpion Therapeutics | July, 17 ,2024 | Series C | $150,000,000 |
| Capstan Therapeutics | March, 21 ,2024 | Series B | $175,000,000 |
| Mirador Therapeutics | March, 26 ,2024 | Unknown | $400,000,000 |
| Alterome Therapeutics, Inc | April, 09 ,2024 | Series B | $132,000,000 |
| Scorpion Therapeutics | July, 17 ,2024 | Series C | $150,000,000 |
| Candid Therapeutics | September, 10 ,2024 | Unknown | $370,000,000 |
| Leal Therapeutics | October, 31 ,2024 | Unknown | $45,000,000 |
| Adcendo | November, 26 ,2024 | Series B | $135,000,000 |
| Angitia Biopharmaceuticals | December, 12 ,2024 | Series C | $120,000,000 |
| Aerin Medical | January, 14 ,2025 | Unknown | $32,500,000 |
| Curevo Vaccine | March, 19 ,2025 | Series B | $110,000,000 |
dezerv.
FalconX
Kristal.AI
Finary
Savart
Sympera AI | $10,000,000 | (Apr 2, 2025)
InfiniLink | $10,000,000 | (Apr 2, 2025)
LightSource | $33,000,000 | (Apr 2, 2025)
Notable Systems | $12,000,000 | (Apr 2, 2025)
LTV.ai | $5,200,000 | (Apr 2, 2025)
